Cardiovascular Risk Associated With Ibrutinib Use in CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study
J. Clin. Oncol 2021 Aug 31;[EPub Ahead of Print], H Abdel-Qadir, N Sabrie, D Leong, A Pang, PC Austin, A Prica, K Nanthakumar, O Calvillo-Argüelles, DS Lee, P ThavendiranathanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.